On course to publish our scientific research and findings.
We are committed to publishing the results from our pre-clinical and clinical research in collaboration with the scientists, physicians, researchers and others with whom we collaborate at medical meetings and in peer-reviewed publications.
| Date | Type | Description | Link |
|---|---|---|---|
| Apr 2022 | Poster | ME-344, a novel isoflavone mitochondrial inhibitor, in combination with venetoclax constitutes a new metabolism-targeted approach to overcome resistance to Bcl-2 inhibition and standard of care treatment in AML, AACR Annual Meeting 2022 |
/sites/meipharma-corp/files/mei-pharma/media/aacr2022-me344-poster-final.pdf |
| Dec 2021 | Poster | A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML via Suppression of Oxidative Phosphorylation and Purine Biosynthesis, 63rd ASH Annual Meeting, December 2021 |
/sites/meipharma-corp/files/mei-pharma/media/ash-2021-me344-venetoclax-aml-fina… |
| Aug 2020 | Journal Papers | Zhang, et al. Voltage-Dependent Anion Channels Influence Cytotoxicity of ME-344, a Therapeutic Isoflavone. J Pharmacol Exp Ther. 2020 Aug;374(2):308-318. |
https://pubmed.ncbi.nlm.nih.gov/32546528/ |
| Jan 2020 | Journal Papers | Quintela-Fandino, et al. Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. Clin Cancer Res. 2020 Jan 1;26(1):35-45. |
https://pubmed.ncbi.nlm.nih.gov/31597662/ |
| Aug 2019 | Journal Papers | Zhang, et al. Isoflavone ME-344 Disrupts Redox Homeostasis and Mitochondrial Function by Targeting Heme Oxygenase 1. Cancer Res. 2019 Aug 15;79(16):4072-4085. |
https://pubmed.ncbi.nlm.nih.gov/31227482/ |
| Jan 2019 | Poster | A randomized phase 0 trial of the mitocondrial inhibitor ME344 or placebo added to the antiangiogenic (Aa) bevacizumab in early HER2-negative breast cancer (E-HERNEBC), ASCO Annual Meeting, June 2019 |
/sites/meipharma-corp/files/mei-pharma/media/2019-asco-me344.pdf |
| Jan 2019 | Journal Papers | Zhang, et al. Pharmacology of ME-344, a novel cytotoxic isoflavone. Adv Cancer Res. 2019;142:187-207 |
https://pubmed.ncbi.nlm.nih.gov/30885362/ |
| Aug 2018 | Poster | Abrogation of resistance against bevacizumab (Bev) by mitochondrial inhibition: a phase 0 randomized trial of Bev plus ME344 or placebo in early HER2-negative breast cancer (HERNEBC), ASCO Annual Meeting, June 2018 |
/sites/meipharma-corp/files/mei-pharma/media/2018-asco-me-344.pdf |
| Jan 2017 | Journal Papers | Diamond, et al. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers. Invest New Drugs. 2017 Oct;35(5):627-633. |
https://pubmed.ncbi.nlm.nih.gov/28283779/ |
| Aug 2016 | Journal Papers | Jeyaraju, et al. A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia. Oncotarget. 2016 Aug 2;7(31):49777-49785. |
https://pubmed.ncbi.nlm.nih.gov/27391350/ |
| Aug 2016 | Journal Papers | Manevich, et al. Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344. J Pharmacol Exp Ther. 2016 Aug;358(2):199-208. |
https://pubmed.ncbi.nlm.nih.gov/27255112/ |
| Jun 2016 | Journal Papers | Navarro, et al. Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics. Cell Rep. 2016 Jun 21;15(12):2705-18. |
https://pubmed.ncbi.nlm.nih.gov/27292634/ |
| Apr 2015 | Journal Papers | Bendell, et al. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Cancer. 2015 Apr 1;121(7):1056-63. |
https://pubmed.ncbi.nlm.nih.gov/25411085/ |
| Apr 2015 | Poster | ME-344, a Novel Isoflavone with Activity as a Mitochondrial Oxygenase Inhibitor. AACR Annual Meeting, Apr 2015 |
/sites/meipharma-corp/files/mei-pharma/pipeline/publications/ME-344%20-%20AACR%… |
| Jan 2015 | Journal Papers | Lim, et al. Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I). Am J Cancer Res. 2015 Jan 15;5(2):689-701. |
https://pubmed.ncbi.nlm.nih.gov/25973307/ |
| Aug 2011 | Journal Papers | Alvero, et al. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther. 2011 Aug;10(8):1385-93. |
https://pubmed.ncbi.nlm.nih.gov/21677151/ |
| Jul 2009 | Journal Papers | Alvero, et al. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer. 2009 Jul 15;115(14):3204-16 |
https://pubmed.ncbi.nlm.nih.gov/19472400/ |